What Leerink Swann stated in December (4 months ago)- Terry
I posted this in late January (this was from Mid-December 2013 the 2025E was a mistype and probably should have read either 2017 or 2018):
Here is their (Joe S) assessment of Insmed last month They have a $22 target currently.
• We believe that INSM shares are poised to appreciate as the
company develops and subsequently commercializes its sole product
Arikace (inhaled liposomal amikacin) in two attractive orphan
disease markets: cystic fibrosis (CF) and non-tuberculous
• We believe that Arikace presents an attractive clinical profile and is
differentiated by its unique biochemical capacity to target evasive
• During 1Q14, we anticipate a readout on Arikace’s safety and
efficacy in the (potentially pivotal) Phase II TARGET study in
American NTM patients.
• We see optionality with INSM shares here after the CLEAR-108
data, which demonstrated that 1x daily Arikace is non-inferior to 2x
daily Tobi in cystic fibrosis. If TARGET is a success, INSM shares
could be worth $30+ on 2025E sales of $1B in NTM/CF. If
TARGET fails, we model a $340MM worldwide market opportunity
for Arikace in CF that could create a ~$9 floor value for the stock
which could be bolstered by Arikace’s potential in other indications
such as non-CF bronchiectasis.
• INSM has three Orange Book listable patents including a
composition of matter patent expiring in 2028 and may be entitled to
additional market exclusivity under Hatch-Waxman, GAIN act
legislation, or QIDP for the NTM indication. Our Outperform rating
reflects our expectation that INSM shares will appreciate as clinical,
regulatory and commercial catalysts are realized and investors
augment their view of the company’s potential."